Full Press Release Details
Eidos Therapeutics Presents Data From Its Phase 1 Clinical Trial Of AG10 At The 22nd Annual Scientific Meeting Of The Heart Failure Society Of America.
BBIO
Eidos Therapeutics Presents Data From Its Phase 1 Clinical Trial Of AG10 At The 22nd Annual Scientific Meeting Of The Heart Failure Society Of America
Key Takeaway: Eidos Therapeutics Presents Data From Its Phase 1 Clinical Trial Of AG10 At The 22nd Annual Scientific Meeting Of The Heart Failure Society Of America
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis